HealthDay News — Semaglutide 2.4mg is associated with superior and clinically meaningful weight loss compared with placebo for adults with overweight or obesity and type 2 diabetes, according to a study published online March 2 in The Lancet.

Melanie Davies, MD, from the University of Leicester in the United Kingdom, and colleagues conducted a phase 3, superiority trial involving adults with a body mass index of ≥27kg/m2 with type 2 diabetes. A total of 1210 participants, recruited from 149 outpatient clinics in 12 countries were randomly assigned to a subcutaneous injection of semaglutide 2.4mg (404 participants), semaglutide 1.0mg (403 participants), or visually matching placebo (403 participants) once a week for 68 weeks, together with a lifestyle intervention.

The researchers found that from baseline to week 68, the estimated change in mean body weight was −9.6% with semaglutide 2.4mg, −7.0% with semaglutide 1.0mg, and −3.4% with placebo. At week 68, the percentage of patients who had achieved weight reductions of at least 5% was higher for those in the semaglutide 2.4 mg group vs placebo group (68.8 vs 28.5%; odds ratio, 4.88). Adverse events occurred more frequently with semaglutide 2.4mg and 1.0mg vs placebo (87.6 and 81.8%, respectively, vs 76.9%).

“These results are exciting and represent a new era in weight management in people with type 2 diabetes — they mark a real paradigm shift in our ability to treat obesity, the results bring us closer to what we see with more invasive surgery,” Davies said in a statement.


Continue Reading

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)